Advancements in lung cancer research through AI and new biomarkers

Researchers are utilizing artificial intelligence and molecular biology to advance cancer diagnosis and drug development. Computer scientists at Stanford Medicine created a simulated biotechnology company using approximately 37,000 AI agents to analyze tens of thousands of human drug studies. The AI identified a pattern where drugs targeting genes acting as 'on/off switches' were 40% more likely to pass Phase 1 clinical trials and 48% more likely to reach the market, while showing 32% fewer harmful side effects. This method has been applied to lung cancer, specifically studying the B7-H3 protein.

In a separate development, researchers from GENyO, the University of Granada, and the Biosanitary Research Institute of Granada have identified the long non-coding RNA TUSC7 as a promising biomarker for non-small cell lung cancer. This biomarker could improve diagnostic precision and help predict how patients respond to specific treatments, addressing the challenge of late-stage diagnoses in one of the world's leading causes of cancer death.